abstract |
The present invention features compositions and methods for enhancing an anti-tumor response by administering an OX40 agonist ( e.g. , an anti-OX40 antibody) and/or an anti-CTLA4 antibody ( e.g. , a CTLA4-blocking antibody) in combination with a cancer therapy. |